Navigation Links
Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
Date:9/23/2013

Atlanta, September 23, 2013 A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting. The study confirmed a disease-specific-survival (DSS) rate of 95 percent when patients received fewer weeks of neoadjuvant (NEO) total androgen suppression (TAS).

The multi-institutional phase III trial, Radiation Therapy Oncology Group (RTOG) 9910, evaluated 1,490 intermediate-risk prostate cancer (PCa) patients from 152 institutions in the U.S. and Canada. Patients were accrued from 2000 to 2004 and followed for an average of 9 years, and the average age of the men was 71 at the time of accrual. The patients were stratified and randomized into two groups―Group 1 consisted of 752 patients who received eight weeks of NEO TAS, and Group 2 consisted of 738 patients who received 28 weeks of NEO TAS. Both groups then received eight weeks of external beam radiation therapy (RT) and concurrent TAS.

Cumulative incidence was used to estimate and test efficacy for DSS, prostate-specific antigen (PSA) failure, locoregional tumor progression and distant metastasis. Overall survival (OS) rates were estimated via the Kaplan-Meier method and efficacy tested with log rank. There were 30 PCa deaths in Group 1, for a 10-year DSS rate of 95 percent; and 24 PCa deaths in Group 2, for a 10-year DSS rate of 96 percent (no statistical difference). There were 200 additional deaths not attributable to PCa in Group 1 for a 10-year OS rate of 66 percent, and 196 such deaths in Group 2, for a 10-year OS rate of 67 percent. By 10 years, 27 percent of patients had a PSA failure (using the newer RTOG-ASTRO definition of nadir+2), 5 percent had PCa recurrence in the prostate (locoregional) and 6 percent had distant metastasis. Hot flashes and erectile dysfunction were more common in Group 2.

"Sometimes, preliminary research leads us to assume that more treatment is better, but this study serves as a strong cautionary note to put the promising treatment to the test," said Thomas Pisansky, MD, lead author of the study and professor of radiation oncology at the Mayo Clinic in Rochester, Minn. "Overall, both groups had very, very good outcomes, but patients assigned to Group 2 had more side effects from androgen suppression than Group 1, who received only eight weeks of NEO TAS. Now, investigators know the upper boundary of how much androgen suppression is needed in this group of patients. The results have substantial importance because they can alter the research strategy to one in which investigation can now concentrate on ways to simplify the treatment and further reduce side effects."


'/>"/>

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. PeopleKeys Develops HR Filtering Tools in Response to Fewer Jobs, Increased Competition in Health Care
2. Twin Cities Home Sales Hit A Hot Summer Pace: 31.4 Percent Fewer Days
3. Longest and largest study of insulin pumps to treat type 1 diabetes in children shows they control blood sugar more effectively and with fewer complications than injections
4. Kwiksure Examines Why Drivers Have Fewer Accidents on Hong Kong Island than in the New Territories
5. Fewer states holding alcohol retailers responsible for harms from illegal service
6. Prostate cancers are fewer, smaller on walnut-enriched diet
7. Fewer Families Struggling to Pay Medical Bills: CDC
8. Healthy lifestyle choices mean fewer memory complaints, poll by UCLA and Gallup finds
9. Integrated stroke care system results in fewer deaths, discharges to long-term care facilities
10. Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup
11. Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology: